Search - tctmd.com

Displaying 41 - 54 of 54

Sort: Relevancy | Date

Presentation ACC 2015

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Presenter: Michael J. Reardon

March 15, 2015

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

News Conference News ACC 2014

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

L.A. McKeown

March 29, 2014

Presentation ACC 2013

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

Presenter: Vinod H. Thourani

March 11, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

Presentation ACC 2013

Impact of Sex on Outcomes Following Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Insights From The PARTNER Experience

Presenter: Ajay J. Kirtane

March 11, 2013

News Conference News ACC 2013

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

L.A. McKeown

March 09, 2013

Presentation ACC 2013

A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis Who Are Not Candidates for Surgery: PARTNER II, Inoperable Cohort

Presenter: Martin B. Leon

March 09, 2013

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

PARTNER: TAVR Remains as Effective as Surgery at 2 Years

March 26, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Video

» Interview

Apixaban After TAVI for Aortic Stenosis: ATLANTIS

May 20, 2021

Video

» Interview

ACC 2019: Outcomes of Transcatheter Aortic Valve Replacement with Balloon-Expandable Sapien3 Valve in Bicuspid Aortic Stenosis: An Analysis of the STS/TVT Registry

March 18, 2019

Advertisement

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Impact of Sex on Outcomes Following Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Insights From The PARTNER Experience

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis Who Are Not Candidates for Surgery: PARTNER II, Inoperable Cohort

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

PARTNER: TAVR Remains as Effective as Surgery at 2 Years

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Apixaban After TAVI for Aortic Stenosis: ATLANTIS

ACC 2019: Outcomes of Transcatheter Aortic Valve Replacement with Balloon-Expandable Sapien3 Valve in Bicuspid Aortic Stenosis: An Analysis of the STS/TVT Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content